Centuple Global

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE396H01019
  • NSEID:
  • BSEID: 531099
INR
37.00
0.7 (1.93%)
BSENSE

Aug 25, 03:32 PM

BSE+NSE Vol: 7.17 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Colinz Labs
Centuple Global
Ishita Drugs
Zenith Health
Desh Rakshak
Venmax Drugs
Welcure Drugs
Shree Ganesh Bio
Cian Healthcare
Bacil Pharma
Dipna Pharmachem

Why is Centuple Global Ltd ?

1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.45
2
Falling Participation by Institutional Investors
  • Institutional investors have decreased their stake by -2.12% over the previous quarter and collectively hold 8.59% of the company
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Centuple Global for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Centuple Global
6.84%
0.11
64.93%
Sensex
-4.88%
-0.36
13.50%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
254.85%
EBIT Growth (5y)
24.49%
EBIT to Interest (avg)
0.45
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
7.07
Tax Ratio
33.62%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.59%
ROCE (avg)
11.21%
ROE (avg)
17.29%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
13
Industry P/E
37
Price to Book Value
10.08
EV to EBIT
9.86
EV to EBITDA
9.86
EV to Capital Employed
10.72
EV to Sales
0.04
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
104.89%
ROE (Latest)
76.14%
Loading Valuation Snapshot...
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company
NET SALES(Latest six months)

At Rs 279.41 cr has Grown at 2,236.20%

0What is not working for the Company
Icon
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...

Here's what is working for Centuple Global

Net Sales - Latest six months
At Rs 279.41 cr has Grown at 2,236.20%
Year on Year (YoY)
MOJO Watch
Sales trend is very positive

Net Sales (Rs Cr)